Related Experiment Videos
Web alert. Oligonucleotide, antibody and peptide therapeutics
1Academic Department of Paediatrics, Imperial College London, St Mary's Campus, Norfolk Place, Paddington, London, W2 1PG, UK. a.stephens@imperial.ac.uk
Current Opinion in Molecular Therapeutics
|May 30, 2003
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
The Use of Dual-Cell-Tracker Dye Staining for the Identification and Characterization of Peanut-Specific T-Cell Subsets.
Methods in molecular biology (Clifton, N.J.)·2019
Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy.
The Journal of allergy and clinical immunology·2014
Peanut allergy: effect of environmental peanut exposure in children with filaggrin loss-of-function mutations.
The Journal of allergy and clinical immunology·2014
IL-9 is a key component of memory TH cell peanut-specific responses from children with peanut allergy.
The Journal of allergy and clinical immunology·2014
Distribution of peanut protein in the home environment.
The Journal of allergy and clinical immunology·2013
Peanut protein in household dust is related to household peanut consumption and is biologically active.
The Journal of allergy and clinical immunology·2013
Gene therapy: Have the risks associated with viral vectors been solved?
Current opinion in molecular therapeutics·2011
Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.
Current opinion in molecular therapeutics·2010
Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.
Current opinion in molecular therapeutics·2010
Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.
Current opinion in molecular therapeutics·2010
Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.
Current opinion in molecular therapeutics·2010
Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.
Current opinion in molecular therapeutics·2010
Projected lives saved and economic value of mRNA cancer immunotherapies in the United States.
Lancet regional health. Americas·2026
Gene Therapy: The Current Trajectory of Clinical and Commercial Translation.
Progress in biophysics and molecular biology·2026